IDO1 and bladder transitional cell carcinoma: These findings highlight the potential of DAU in inhibiting BLCA progression and identify IDO1 as a promising therapeutic target, and suggest that targeting ferroptosis pathways may amplify the anti‐tumor effects of IDO1 inhibitors.